Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Angiogenesis >> BTK

BTK

BTK (Bruton's tyrosine kinase) binds PIP3 and phosphorylates phospholipase C, plays a crucial role in B cell maturation as well as mast cell activation.

Products for  BTK

  1. Cat.No. Product Name Information
  2. GC34069 (±)-Zanubrutinib ((±)-BGB-3111) (±)-Zanubrutinib ((±)-BGB-3111) ((±)-BGB-3111) is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor. (±)-Zanubrutinib ((±)-BGB-3111) Chemical Structure
  3. GC67857 (R)-Elsubrutinib

    (R)-ABBV-105

     (R)-Elsubrutinib Chemical Structure
  4. GC63797 (S)-Sunvozertinib

    (S)-DZD9008

     (S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against EGFR exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC50=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively). (S)-Sunvozertinib also inhibits BTK. (S)-Sunvozertinib Chemical Structure
  5. GC60551 Acalabrutinib D4

    ACP-196-d4

     Acalabrutinib D4 Chemical Structure
  6. GC15453 ACP-196

    ACP-196

     ACP-196 (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. ACP-196 binds covalently to Cys481 in the ATP-binding pocket of BTK. ACP-196 demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). ACP-196 Chemical Structure
  7. GC31679 ARQ 531

    MK-1026

    ARQ 531 (MK-1026) is a reversible non-covalent and orally active inhibitor of Bruton’s Tyrosine Kinase (BTK), with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.

     ARQ 531 Chemical Structure
  8. GC70685 Atuzabrutinib Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosine kinase) inhibitor. Atuzabrutinib Chemical Structure
  9. GC13562 AVL-292

    AVL292;AVL 292

     A covalent BTK inhibitor AVL-292 Chemical Structure
  10. GC63846 BIIB091 BIIB091 is a highly selective, reversible and orally active BTK inhibitor for treating autoimmune diseases. BIIB091 Chemical Structure
  11. GC74040 BIIB129 BIIB129 is a covalent, selective, small molecule inhibitor of Bruton's tyrosine kinase (BTK) capable of penetrating the blood-brain barrier. BIIB129 Chemical Structure
  12. GC68373 BLK-IN-2 BLK-IN-2 Chemical Structure
  13. GC31760 BMS-935177 BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk) with an IC50 of 3 nM. BMS-935177 Chemical Structure
  14. GC31713 BMS-986142 A BTK inhibitor BMS-986142 Chemical Structure
  15. GC32844 BMS-986195

    BMS-986195

     BMS-986195 (BMS-986195) is a highly potent, selective covalent, irreversible inhibitor of Bruton's tyrosine kinase (BTK), with an IC50 of 0.1 nM. BMS-986195 Chemical Structure
  16. GC11063 BMX-IN-1

    BMX Inhibitor 1

     A selective BMX and BTK inhibitor BMX-IN-1 Chemical Structure
  17. GC19333 BTK IN-1

    BTK-IN-1

     BTK IN-1 is a potent BTK inhibitor, with an IC50 of <100 nM. BTK IN-1 Chemical Structure
  18. GC35561 Btk inhibitor 1 Btk inhibitor 1 is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM. Btk inhibitor 1 Chemical Structure
  19. GC35562 Btk inhibitor 1 hydrochloride Btk inhibitor 1 hydrochloride Chemical Structure
  20. GC10924 Btk inhibitor 1 R enantiomer Btk inhibitor 1 R enantiomer is an impurity of Ibrutinib. Btk inhibitor 1 R enantiomer can be used in synthesis of Btk inhibitor 1 R enantiomer Ibrutinib dimer and Btk inhibitor 1 R enantiomer adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM. Btk inhibitor 1 R enantiomer Chemical Structure
  21. GC35563 Btk inhibitor 1 R enantiomer hydrochloride Btk inhibitor 1 R enantiomer hydrochloride is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM. Btk inhibitor 1 R enantiomer hydrochloride Chemical Structure
  22. GC67940 BTK inhibitor 10 BTK inhibitor 10 Chemical Structure
  23. GC62498 BTK inhibitor 17 BTK inhibitor 17 is a potent and orally active irreversible BTK inhibitor with an IC50 of 2.1 nM. BTK inhibitor 17 Chemical Structure
  24. GC64360 BTK inhibitor 18 BTK inhibitor 18 is a potent, selective,orally active and covalent Btk inhibitor with a IC50 of 142 nM. BTK inhibitor 18 Chemical Structure
  25. GC32007 Btk inhibitor 2

    BGB-3111 analog

     Btk inhibitor 2 (BGB-3111 analog) is a Bruton's tyrosine kinase (BTK) inhibitor extracted from patent US 20170224688 A1. Btk inhibitor 2 Chemical Structure
  26. GC73854 BTK-IN-29 BTK-IN-29 (compound 14) is an inhibitor of Btk. BTK-IN-29 Chemical Structure
  27. GC33064 CG-806 (Luxeptinib)

    CG-806

     CG-806 (Luxeptinib) (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. CG-806 (Luxeptinib) induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells. CG-806 (Luxeptinib) Chemical Structure
  28. GC13365 CGI-1746 A potent, selective BTK inhibitor CGI-1746 Chemical Structure
  29. GC35683 CHMFL-BTK-01 CHMFL-BTK-01 (compound 9) is a highly selective irreversible BTK inhibitor, with an IC50 of 7 nM. CHMFL-BTK-01 (compound 9) potently inhibited BTK Y223 auto-phosphorylation. CHMFL-BTK-01 Chemical Structure
  30. GC35684 CHMFL-EGFR-202 CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC50s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. CHMFL-EGFR-202 exhibits ?10-fold selectivity for EGFR L858R/T790M against the EGFR wild-type in cells. CHMFL-EGFR-202 adopts a covalent “DFG-in-C-helix-out” inactive binding conformation with EGFR, with strong antiproliferative effects against EGFR mutant-driven nonsmall-cell lung cancer (NSCLC) cell lines. CHMFL-EGFR-202 Chemical Structure
  31. GC13439 CNX-774 BTK inhibitor, orally active, irreversible and selective CNX-774 Chemical Structure
  32. GC64819 Elsubrutinib

    ABBV-105

     Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor。The IC50 of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib Chemical Structure
  33. GC34062 Evobrutinib (M2951) Evobrutinib, as an orally, highly selective, covalent Bruton's tyrosine kinase inhibitor, was well‐tolerated and effective. Evobrutinib (M2951) Chemical Structure
  34. GC73490 GBD-9 GBD-9 is a double-mechanism degrader that efficiently degrades BTK and GSPT1 by recruiting the E3 ligase cereblon (CRBN). GBD-9 Chemical Structure
  35. GC11995 GDC-0834 GDC-0834 is the S-enantiomer of GDC-0834. GDC-0834 Chemical Structure
  36. GC36127 GDC-0834 Racemate Racemic form of GDC-0834 GDC-0834 Racemate Chemical Structure
  37. GC19162 GDC-0853

    RG-7845

     GDC-0853 (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (Btk) inhibitor with Kis of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk, and the C481S, C481R, T474I, T474M mutants. GDC-0853 has the potential for rheumatoid arthritis and systemic lupus erythematosus research. GDC-0853 Chemical Structure
  38. GC39194 Ibrutinib D5 Ibrutinib D5 (PCI-32765 D5) is a deuterium labeled Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor. Ibrutinib D5 Chemical Structure
  39. GC60197 Ibrutinib deacryloylpiperidine Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM. Ibrutinib deacryloylpiperidine Chemical Structure
  40. GC36289 Ibrutinib-biotin Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker, extracted from patent WO2014059368A1 Compound 1-5, has an IC50 of 0.755-1.02 nM for BTK. Ibrutinib-biotin Chemical Structure
  41. GC73427 JNJ-64264681 JNJ-64264681 is a potent, orally active, selective and irreversible covalent BTK inhibitor. JNJ-64264681 Chemical Structure
  42. GC73364 JS25 JS25 is a selective and covalent inhibitor of BTK that inactivates BTK with an IC50 value of 5.8 nM by chelating Tyr551. JS25 Chemical Structure
  43. GC73775 KIN-8194 KIN-8194 is an orally active dual inhibitor of HCK and BTK, with IC50 values of 0.915 and <0.495 nM, respectively. KIN-8194 Chemical Structure
  44. GC73414 Larotinib Larotinib is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target with an IC50 of 0.6 nM. Larotinib Chemical Structure
  45. GC14857 LFM-A13 BTK-specific tyrosine kinase inhibitor LFM-A13 Chemical Structure
  46. GC36661 MT-802 MT-802 is a potent BTK degrader based on Cereblon ligand, with a DC50 of 1 nM. MT-802 Chemical Structure
  47. GC62255 N-piperidine Ibrutinib hydrochloride N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent BTK inhibitor with IC50s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively. N-piperidine Ibrutinib hydrochloride can be used as a BTK ligand in the synthesis of a series of PROTACs, such as SJF620. SJF620 is a potent PROTAC BTK degrader with a DC50 of 7.9 nM. N-piperidine Ibrutinib hydrochloride Chemical Structure
  48. GC73434 NRX-0492 NRX-0492 is an orally active and potent degrader of BTK. NRX-0492 Chemical Structure
  49. GC69600 NX-2127

    NX-2127 is an orally effective BTK inhibitor that can induce the degradation of mutated BTKC481S in cells. NX-2127 inhibits the proliferation of TMD8 cells with the BTKC481S mutation more effectively than Ibrutinib. NX-2127 catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3), corresponding to concentrations of 25 nM and 54 nM, respectively. NX-2127 stimulates T cell activation and increases IL-2 production in primary human T cells.

     NX-2127 Chemical Structure
  50. GC13219 ONO-4059

    GS-4059 analog

     ONO-4059 is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor. ONO-4059 Chemical Structure
  51. GC36861 PCI 29732 A multi-kinase inhibitor PCI 29732 Chemical Structure
  52. GC13812 PCI-32765 (Ibrutinib)

    Imbruvica, PCI 32765

     PCI-32765 (Ibrutinib) is an irreversible selective inhibitor of Bruton s tyrosine kinase (BTK) that selectively targets its kinase domain and modulates BTK downstream signaling by reducing its phosphorylating capacity with IC50 of 0.5 nM in cell-free assays. PCI-32765 (Ibrutinib) Chemical Structure
  53. GC12921 PCI-32765 Racemate PCI-32765 Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM. PCI-32765 Racemate Chemical Structure
  54. GC30155 PCI-33380 PCI-33380 is an irreversible and selective Bruton's Tyrosine Kinase (BTK) inhibitor (fluorescent probe). PCI-33380 Chemical Structure
  55. GC34709 PF-06250112 PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5 nM, shows inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC with IC50s of 0.9 nM and 1.2 nM, respectively. PF-06250112 Chemical Structure
  56. GC62515 Pirtobrutinib

    LOXO-305, LY3527727

     Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM. Pirtobrutinib Chemical Structure
  57. GC31339 PRN1008

    PRN1008

     PRN1008 (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton's Tyrosine Kinase (BTK), with an IC50 of 1.3 nM. PRN1008 Chemical Structure
  58. GC37048 QL47 QL47, a broad-spectrum antiviral agent, inhibits dengue virus and other RNA viruses. QL47 Chemical Structure
  59. GC38375 Remibrutinib Remibrutinib, is a potent and orally active bruton tyrosine kinase (BTK) inhibitor with an IC50 value of 1 nM. Remibrutinib Chemical Structure
  60. GC11230 RN486 Btk inhibitor,potent and selective RN486 Chemical Structure
  61. GC73373 RSH-7 RSH-7 is a potent BTK and FLT3 inhibitor with IC50s of 47, 12 nM, respectively. RSH-7 Chemical Structure
  62. GC62614 SJF620 hydrochloride SJF620 hydrochloride is a PROTAC connected by ligands for Cereblon and Btk with a DC50 of 7.9 nM. SJF620 contains a Lenalidomide analog for recruiting CRBN. SJF620 hydrochloride Chemical Structure
  63. GC37672 Spebrutinib besylate

    AVL-292 benzenesulfonate; CC-292 besylate

     Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a potent inhibitor of Btk kinase activity (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s) in biochemical assays. Spebrutinib besylate Chemical Structure
  64. GC64120 TAK-020 TAK-020 is a covalent Btk inhibitor, which becomes the clinical candidate. TAK-020 Chemical Structure
  65. GC33821 Tirabrutinib (ONO-4059)

    GS-4059, ONO-WG-307, Tirabrutinib

     Tirabrutinib (ONO-4059) (ONO-4059) is an orally active Bruton's Tyrosine Kinase (BTK) inhibitor (can cross the blood-brain barrier (BBB)), with an IC50 of 6.8 nM. Tirabrutinib (ONO-4059) Chemical Structure
  66. GC34097 Tirabrutinib hydrochloride (ONO-4059 (hydrochloride))

    GS-4059, ONO-WG-307

     Tirabrutinib (ONO-4059) hydrochloride is an orally active Bruton's Tyrosine Kinase (BTK) inhibitor (can cross the blood-brain barrier (BBB)), with an IC50 of 6.8 nM. Tirabrutinib hydrochloride (ONO-4059 (hydrochloride)) Chemical Structure
  67. GC63229 TL-895 TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. TL-895 Chemical Structure
  68. GC63232 Tolebrutinib

    SAR442168; PRN2246

     Tolebrutinib (SAR442168) is a potent, selective, orally active and brain-penetrant inhibitor of Bruton tyrosine kinase (BTK), with IC50s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively. Tolebrutinib Chemical Structure
  69. GC73855 UBX-382 UBX-382 is an orally available proteolysis-targeting chimeras (PROTACs) that target BTK to inactivate B-cell receptor signaling. UBX-382 Chemical Structure
  70. GC34077 Vecabrutinib (SNS-062) Vecabrutinib (SNS-062) (SNS-062) is a potent, noncovalent BTK and ITK inhibitor, with Kd values of 0.3 nM and 2.2 nM, respectively. Vecabrutinib (SNS-062) shows an IC50 of 24 nM for ITK. Vecabrutinib (SNS-062) Chemical Structure
  71. GC34075 Zanubrutinib (BGB-3111)

    BGB-3111

     Zanubrutinib (BGB-3111) (BGB-3111) is a selective Bruton tyrosine kinase (Btk) inhibitor. Zanubrutinib (BGB-3111) Chemical Structure

70 Item(s)

per page

Set Descending Direction